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ABSTRACT – Purpose: This study was 
performed to compare the 2-nitroimidazole 
derivatives [124I]IAZA, [18F]FAZA and well 
known [18F]FMISO in visualization of tumor 
hypoxia in a mouse model of human cancer using 
small animal PET. Methods: PET imaging of 
female Balb/c nude mice bearing A431 tumors on 
a Phillips Mosaic small animal PET scanner was 
performed 3 h p.i. for all three tracers. Mice 
injected with [124I]IAZA were scanned again after 
24 h and 48 h. In addition to the mice breathing 
air, in the case of [18F]FAZA and [124I]IAZA a 
second group of mice for each tracer was kept in 
an atmosphere of carbogen gas (5 % of CO2 + 95 
% of O2; from 1 h before to 3 h after injection) to 
evaluate the oxygenation dependency on uptake 
(all experiments n = 4). After the final PET scan 
animals were sacrificed and biodistribution was 
studied. Results: Mice injected with [18F]FAZA 
displayed significantly higher tumor-to-
background (T/B) ratios (5.19 ± 0.73) compared 
to those injected with [18F]FMISO (3.98 ± 0.66; P 
< 0.05) or [124I]IAZA (2.06 ± 0.26; P < 0.001) 3 h 
p.i. Carbogen breathing mice showed lower ratios 
([18F]FAZA: 4.06 ± 0.59; [124I]IAZA: 2.02 ± 
0.36). The T/B ratios increased for [124I]IAZA 
with time (24 h: 3.83 ± 0.61; 48 h: 4.20 ± 0.80), 
but after these late time points the absolute whole 
body activity was very low, as could be seen from 
the biodistribution data (< 0.1 %ID/g for each 
investigated organ) and ratios were still lower 
than for [18F]FAZA 3 h p.i. Due to de-iodination 
uptake in thyroid was high. Biodistribution data 
were in good agreement with the PET results. 
Conclusions: [18F]FAZA showed superior 
biokinetics compared to [18F]FMISO and 
[124I]IAZA in this study. Imaging at later time 
points that are not possible with the short-lived 
18F-labeled tracers resulted in no advantage for 
[124I]IAZA, i. e., tumor-to-normal tissue ratios 
could not be improved. 
 
INTRODUCTION 
 
Oxygen deficiency is a common characteristic of 
solid tumors leading to decreased sensitivity to 
radiation therapy and anticancer drugs. Therefore, 
hypoxia is an important adverse prognostic factor 
for tumor progression and resistance to therapy 
(1-3) and identification of hypoxic tumor tissue is 
of high clinical relevance. 
 
Positron emission tomography (PET) offers the 
possibility to detect hypoxia non-invasively in 
vivo (4). To date the most commonly used tracer 
to visualize and quantify hypoxia using PET has 
been [18F]fluoromisonidazole ([18F]FMISO; 
Figure 1) (5-8). Its uptake mechanism has been 
validated to be oxygenation-specific (9,10). More 
recently, the 18F labeled azomycin arabinoside 
([18F]FAZA; Figure 1; ref. 11) has been 
investigated and found to have superior 
pharmacokinetics compared to [18F]FMISO. This 
is primarily due to faster clearance from normal 
tissue resulting in an enhanced tumor-to-
background ratio (12-14). Another azomycin-
based nucleoside iodoazomycin arabinoside 
(IAZA; Figure 1) has been labeled with various 
iodine isotopes (123I, 125I and 131I) and proved its 
value for detection of hypoxia in vitro (15) and in 
vivo (16,17). PET imaging using IAZA labeled 
with iodine-124 (T½: 4.18 d; Iβ+: 25 %) has not 
been reported to date. However, [124I]iodo-
azomycin galactoside was studied in small animal 
PET experiments in tumor bearing mice and 
demonstrated its potential for hypoxia imaging 
(18).  
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Figure 1: Chemical structures of [18F]FMISO (left) and the azomycin (i.e. 2-nitroimidazole) 
arabinoside derivatives (right) for [18F]FAZA (*X = 18F) and [124I]IAZA (*X = 124I). 
 
Recent adaptation of PET for use with small 
animals has created a valuable opportunity for in 
vivo characterization of molecular mechanisms 
regulating tumor phenotype such as hypoxia.  
 
Herein we report results of a comparative small 
animal imaging study, for the first time 
comparing [124I]IAZA, [18F]FAZA and 
[18F]FMISO PET together with biodistribution 
studies. Iodine-124 offers the opportunity of 
imaging at late time points (here 24 h and 48 h) to 
investigate possible enhancement of hypoxia 
imaging, compared to imaging at 3 h p. i. with 
[18F]FAZA or the more widely used hypoxia 
tracer [18F]FMISO. To demonstrate the oxygen 
dependence of tracer uptake, animals were 
divided into groups, breathing either air or 
carbogen. 
 
METHODS 
 
Materials 
[18F]Fluoromisonidazole ([18F]FMISO) was 
purchased from the Austin Hospital PET Centre, 
Melbourne. Specified radiochemical purity was > 
95 % and specific activity was between 55 and 
111 GBq/µmol at end of synthesis (EOS). Sodium 
[124I]iodide was from Ritverc, St. Petersburg, 
Russia. [18F]Fluoride was produced in house 
(Peter MacCallum Cancer Institute) using an 
OSCAR 7 cyclotron (Oxford Instruments, 
Oxford, UK) by the 18O(p,n)18F nuclear reaction. 
The precursor for [18F]FAZA and [124I]IAZA 
synthesis was a kind gift from Drs. Leonard I. 
Wiebe and Piyush Kumar, University of Alberta, 
Canada. [18F]FAZA was labeled as described 
previously (19,20), using a TRACERlab MX 
synthesizer (GE Healthcare, Liège, Belgium) 
coupled with a preparative HPLC system. The 
product was obtained in a radiochemical purity of 
> 98 % and a specific activity of 118 GBq/µmol 
(EOS). [124I]IAZA was prepared by isotopic 
[124I]iodine exchange using modified literature 
methods (21) yielding the product in > 97 % 
radiochemical purity. Specific activity was 41 
GBq/µmol (EOS). Final purity, radiochemical 
identity and specific activity of tracers were 
assessed by HPLC, following standard protocols. 
 
Tumor growth, implantation and imaging 
All experiments complied with current laws of 
Australia including ethics approval. A431 human 
squamous cell carcinoma cells (ATCC) were 
cultured in alpha MEM supplemented with 10 % 
FBS in 5 % CO2 in air at 37°C. Female Balb/c 
nude mice 8-11 weeks old were inoculated s.c. on 
the right forelimb with 3 x 106 A431 cells in PBS. 
Tumors were measured twice weekly using 
electronic calipers and tumor volumes calculated 
using the formula [volume = length/2 x width2]. 
Once tumor volumes had reached an average of 
150 mm3, animals were randomized into 5 groups 
of 4 animals per group. Animals were injected via 
lateral tail vein with 14-22 MBq [18F]FMISO, 
[18F]FAZA or [124I]IAZA in 100 μL of saline. 
Four animals to be injected with [18F]FAZA and 
[124I]IAZA were kept in a chamber equilibrated 
with carbogen gas (5% CO2 in O2) for one hour 
prior to injection and during the first 3 h tracer 
uptake period while the remaining mice were kept 
in room air during this period. There was no 
disturbance to their food and water supply. 
 
Animals were anaesthetized by inhalation of 2.5 
% isoflurane / 50 % O2 in air (flow rate 200 
mL/min) approximately 3 h post-tracer injection 
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and scanned for 5 – 10 min on a Phillips Mosaic 
small animal PET scanner. Animals injected with 
[124I]IAZA were rescanned at 24 and 48 h post 
injection. PET images were reconstructed using 
the OSEM algorithm (22,23) and images 
displayed using standard image software available 
on the scanner. Tracer uptake was measured using 
region-of-interest (ROI) software on the scanner 
workstation. Briefly, elliptical ROIs were 
manually placed around the tumor and a 
background region on transaxial slice images 
displayed on the workstation. The background 
ROI was chosen to represent tracer present within 
the blood pool and non-tumor tissue, excluding 
regions of increased uptake such as GI tract. 
Maximum, minimum and average pixels within 
the ROI per slice were automatically stored as 
data files. Uptake ratios were calculated by 
dividing the maximum value of pixels within a 
tumor ROI by the average value of pixels within 
the background ROI. The resolution of the 
Mosaic scanner is 2.2 mm and the average tumor 
diameter for all groups of animals was greater 
than 4 mm on all imaging days, therefore 
correction for partial volume effect was not 
required. The axial FOV of the scanner is 12 cm, 
which encompassed the whole of the mouse 
during scanning. 
 
Biodistribution 
Following final PET scans animals were 
sacrificed. Blood, tumor and a range of tissues 
were removed, washed with saline if necessary, 
then weighed and placed into flat bottom tubes. 
Disintegrations at 511 keV ± 15 % were 
quantified in a well counter (187-950-A100 
MCA, Biomedex Medical Systems) attached to a 
multichannel analyzer interfaced with Atomlabs 
950 software (Biomedex Medical Systems). 
 
Statistics 
Results are expressed as mean values of 
parameters ± standard deviation (SD). Unpaired 
student’s t tests were used to determine the 
statistical significance of differences between 
measured quantities in groups of animals. P < 
0.05 was considered statistically significant. 
 
RESULTS 
 
Biodistribution data 
Data for tissue uptake of [18F]FMISO and 
[18F]FAZA 3 h post injection and of [124I]IAZA 
after 48 h are presented in Table 1. For all organs 
uptake was substantially higher for [18F]FMISO 
than for [18F]FAZA with the largest differences 
for lung, liver, kidneys and small intestine (more 
than a factor of 3). The organ with the highest 
uptake was the liver for both markers. Clearance 
from blood was much faster for [18F]FAZA. 
Tumoral uptake of [18F]FMISO (3.43 ± 0.77) was 
approximately two times higher than for 
[18F]FAZA (1.88 ± 0.17). Nevertheless, tumor-to-
blood ratio was significantly higher for 
[18F]FAZA (5.13 ± 0.75 compared to 3.33 ± 0.20 
for [18F]FMISO; P < 0.01), while for tumor-to-
muscle ratios this effect was less marked (3.05 ± 
0.73 vs. 2.76 ± 0.73). Comparison of [18F]FAZA 
uptake in mice breathing air or carbogen showed 
lower tumor-to-blood and tumor-to-muscle ratios 
for the latter, as expected (T/Bl: 5.13 ± 0.75 vs. 
3.99 ± 0.54; T/M: 3.05 ± 0.73 vs. 1.99 ± 0.90). 
Interestingly, tumor uptake showed no significant 
difference, but background uptake in non-tumor 
tissues was higher in the case of carbogen 
breathing animals. 
 
In the case of [124I]IAZA animals were sacrificed 
directly after the 48 h PET scan and tissue uptake 
values determined. After 48 h of uptake the 
overall radioactivity in all tissues was below 0.1 
%ID/g, even in tumors. Tumor-to-muscle ratios 
were significantly higher than for [18F]FAZA 
after 3h of uptake, both for air (P < 0.002) and for 
carbogen (P < 0.001) breathing mice. The 
difference in tumor-to-blood or tumor-to-muscle 
ratios was lower for [124I]IAZA comparing air and 
carbogen breathing animals (T/Bl: 5.28 ± 0.29 vs. 
5.02 ± 0.44; T/M: 6.59 ± 1.05 vs. 5.74 ± 0.31), 
possibly due to an equalizing effect within 48 h, 
as carbogen breathing was stopped after 3 h. 
 
Animal PET imaging 
In all PET images, uptake was clearly visible in 
tumors for all three tracers, i.e. for [18F]FMISO 
and [18F]FAZA 3 h p.i. and [124I]IAZA after 3 h, 
24 h and 48 h. Comparison of the quantitative 
analysis of the tumor-to-background ratios from 
imaging data after 3 h is presented in Figure 2 in 
mice breathing air, T/B ratio was significantly 
higher for [18F]FAZA than for [18F]FMISO (5.19 
± 0.73 vs. 3.98 ± 0.66; P < 0.05). At this time 
point T/B ratio for [124I]IAZA was much lower 
and there was no difference between animals 
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Table 1: Effect of carbogen breathing on biodistribution of PET hypoxia tracers in tissues of A431 tumor bearing 
mice. 
 [18F]FMISOa [18F]FAZAb [124I]IAZAc 
Tissue Air Air Carbogen Air Carbogen 
Blood 1.034 ± 0.225 0.375 ± 0.075 0.449 ± 0.071 0.016 ± 0.002 0.020 ± 0.002 
Heart 0.732 ± 0.331 0.482 ± 0.070 0.618 ± 0.089 0.026 ± 0.006 0.032 ± 0.004 
Lung 1.236 ± 0.438 0.339 ± 0.052 0.477 ± 0.075 0.018 ± 0.001 0.023 ± 0.003 
Liver 4.548 ± 2.100 1.325 ± 0.384 2.401 ± 1.285 0.057 ± 0.003 0.075 ± 0.011 
Spleen 0.877 ± 0.307 0.347 ± 0.033 0.528 ± 0.124 0.011 ± 0.001 0.012 ± 0.001 
Kidney 1.621 ± 0.640 0.488 ± 0.099 0.798 ± 0.290 0.025 ± 0.002 0.030 ± 0.003 
Muscle 1.259 ± 0.167 0.655 ± 0.211 1.079 ± 0.590 0.013 ± 0.002 0.017 ± 0.002 
Stomach 0.865 ± 0.253* 0.550 ± 0.058 0.634 ± 0.323 0.040 ± 0.011 0.039 ± 0.003 
Small intestine 2.196 ± 1.112 0.629 ± 0.051 0.965 ± 0.388 0.010 ± 0.001 0.011 ± 0.002 
Tumor 3.433 ± 0.770 1.883 ± 0.170 1.794 ± 0.418 0.086 ± 0.005 0.097 ± 0.013 
T/Bl ratio 3.325 ± 0.201 5.132 ± 0.750 3.988 ± 0.537 5.284 ± 0.289 5.016 ± 0.443 
T/M ratio 2.764 ± 0.725 3.050 ± 0.734 1.988 ± 0.904 6.590 ± 1.053 5.740 ± 0.306 
a) Radioactivity in tissues of animals breathing room air at 3h after injection of [18F]FMISO. 
b) Animals breathing either air or carbogen at 3h after injection of [18F]FAZA. 
c) Animals breathing either air or carbogen at 48 h after injection of [124I]IAZA. 
Note: Data are presented as %ID/g ± SD; n = 4, *n = 3. 
 
 
breathing air (2.06 ± 0.26) and carbogen (2.02 ± 
0.36). In case of [18F]FAZA, mean T/B ratio was 
approximately 20 % lower in mice breathing 
carbogen (4.06 ± 0.59). 
 
In mice injected with [124I]IAZA tumor-to-
background activity contrast increased much 
more slowly than that for [18F]FMISO and 
[18F]FAZA. Figure 3 shows representative images 
of 2 air breathing mice at 3 h, 24 h and 48 h post 
[124I]IAZA injection. As can be seen, T/B ratio 
increased with time; at 3 h p.i. most of the 
radioactivity was in the abdomen and the 
intestinal tract. The 24 h p.i. scans showed little 
background activity, excepting stomach and 
thyroid, as animals did not receive thyroid 
blockade with iodine supplementation. This most 
likely reflects substantial de-iodination of IAZA 
in vivo. Images at 48 h looked similar to those at 
24 h, however, the total activity remaining was 
quite low. 
 
The quantitative data (Figure 4) show an increase 
in T/B ratio at 24 h in mice breathing air to 3.83 ± 
0.61 and to 4.20 ± 0.80 at 48 h. In mice breathing 
carbogen the ratio was 3.47 ± 0.52 at 24 h and 
3.44 ± 0.88 at 48 h p.i. Although the tumor-to-
background ratios increased for mice injected 
with [124I]IAZA with time, they were still lower 
than for those injected with [18F]FAZA after 3 h 
(4.20 ± 0.80 and 3.44 ± 0.88 vs. 5.19 ± 0.73 and 
4.06 ± 0.59). The difference in T/B ratio between 
mice breathing air and mice breathing carbogen 
was less marked for [124I]IAZA than for 
[18F]FAZA, although there appears to be a trend 
toward reduced T/B ratio in the [124I]IAZA 
carbogen group over time (Figure 4).  
 
DISCUSSION 
 
Tumor hypoxia can lead to a reduced sensitivity 
to radiation and anticancer drugs. As tumor 
hypoxia seems to be a predictive factor for tumor 
response to therapy, its measurement may be  
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Figure 2: Tumor uptake of PET tracers based on image analysis. Tumor-to-background ratios 3 h 
p.i. of [18F]FMISO, [18F]FAZA and [124I]IAZA in Balb/c nude mice bearing A431 tumor, breathing 
either air or carbogen (Data are presented as mean with error bars indicating SD; for SD numbers 
see text; n = 4). 
 
 
 
Figure 3: PET images of mice injected with [124I]IAZA. Representative images 3 h, 24 h and 48 h 
following injection of [124I]IAZA in two mice (I and II) breathing air; head at the top, tumor on left 
shoulder (arrow). Highest uptake in thyroid after 24h and 48 h. 
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Figure 4: Tumor uptake of [124I]IAZA over 48 hours post injection. Tumor-to-background ratios of 
[124I]IAZA 3 h, 24 h and 48 h p.i. in Balb/c nude mice bearing A431 tumor, breathing either air or 
carbogen (Data are presented as mean with error bars indicating SD; for SD numbers see text; n = 
4). 
 
relevant to individualized and therefore optimized 
treatment planning (24-26) as well as an efficient 
therapy control (27). The aim of the current study 
was to investigate the potential of IAZA labeled 
with I-124 as a PET hypoxia tracer in comparison 
with its F-18 analog [18F]FAZA and the more 
established PET hypoxia tracer [18F]FMISO. 
 
Optimum results in PET imaging depend 
predominantly on the pharmacokinetics of the 
radiotracer and the half-life of the radionuclide. 
Previous studies have shown that tumor-to-
background ratios increase with uptake time in 
case of both [18F]FMISO and [18F]FAZA (12,13) 
and uptake times of approximately 3 h were found 
favorable in these small animal experiments due 
to the half-life of F-18. Using I-124 with its 
longer half-life gives the possibility of longer 
uptake times and late imaging. In the study 
presented here, 24 h and 48 h were chosen as late 
time points for imaging. At 3 h p.i. [18F]FAZA 
gave the highest T/B ratio, most likely due to 
slower clearance of [18F]FMISO from normal 
tissues. These comparative results are in very 
good agreement with previous studies (13). For 
[124I]IAZA clearance was much slower. One 
reason for this effect may be attributed to the 
different lipophilicities of the tracers. Partition 
coefficients (P) for the three compounds are 1.10 
for FAZA, 2.60 for FMISO and 4.98 for IAZA 
(11). The most hydrophilic tracer, [18F]FAZA 
showed the best clearance. At 24 h and 48 h p.i. 
clearance was very good for [124I]IAZA, with the 
thyroid remaining as the only tissue with higher 
uptake than the tumor. However, T/B ratios for 
[124I]IAZA at 48 h were slightly lower than for 
[18F]FAZA after 3 h. The hypothesis that longer 
uptake times would result in significantly 
improved T/B ratios for [124I]IAZA could not be 
confirmed in this study. The major disadvantage 
of imaging at such late time points is the low 
absolute whole body activity after 48 h. From 24 
h to 48 h there was almost no improvement in 
image quality. Therefore, it may be even 
advantageous to image after 12 h, with possibly 
still good clearance, some reduction in T/B ratio 
but higher count rates with a given administered 
activity. Blocking the thyroid by prior 
administration of iodide to the animals may be 
desirable.  
 
Carbogen breathing resulted in reduced T/B 
ratios, particularly at the 3 h time point 
demonstrating again the oxygen dependence of 
uptake of the azomycin derivatives. This was 
more pronounced in the case of [18F]FAZA and 
less so for [124I]IAZA. 
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Figure 5: Regression analysis of data derived from ex vivo counting versus PET imaging for mice 
injected with [124I]IAZA. Correlation of T/M ratio (from biodistribution) and T/B ratio (from small 
animal PET) 48 h after injection of [124I]IAZA. Data are from 8 animals breathing air or carbogen 
(regression line y = 0.76x – 0.87; adjusted r2 = 0.46; P < 0.07; dotted lines: 95 % confidence 
intervals). 
 
PET results were in good agreement with the 
biodistribution data, both qualitatively and 
quantitatively as shown for [124I]IAZA (Figure 5) 
by comparing T/B ratios derived from PET with 
the T/M ratios derived from the tissue assays. 
Regression analysis resulted in a linear correlation 
for this tracer (regression line y = 0.76x – 0.87; 
adjusted r2 = 0.46; P < 0.07; dotted lines: 95 % 
confidence intervals). 
 
CONCLUSIONS 
 
Although the number of animals involved in this 
study was limited, the results confirm the 
favorable properties of [18F]FAZA over 
[18F]FMISO for hypoxia imaging with PET due to 
its better clearance from background tissues after 
3 h p.i. Oxygen dependent uptake was 
demonstrated for [18F]FAZA by having one group 
of mice breathing air, the other carbogen. To our 
knowledge, this is the first report of the use of 
[124I]IAZA in a small animal PET study. While    
3 h [124I]IAZA PET images showed a high 
background, after 24 h and 48 h background was 
very low (except for thyroid, for which iodide 
blocking would be advantageous). However, 
tumor activity was low as well, resulting in T/B 
ratios comparable to those of [18F]FMISO, but 
lower than for [18F]FAZA. Ex-vivo 
biodistribution data confirmed PET imaging 
findings. 
 
From the data presented here [18F]FAZA appears 
to have superior properties for hypoxia imaging 
with PET compared to [18F]FMISO and 
[124I]IAZA. Nevertheless, further validations of 
[124I]IAZA are necessary (e.g. at time points 
between 3 and 24 h) to investigate its value for 
hypoxia PET imaging particularly at later time 
points. 
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